Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up

Sanofi (NASDAQ:SNY | SNY Price Prediction) is carrying the Nuvaxovid COVID-19 shot into the fall vaccination season, and buyers are rewarding shares of licensor Novavax (NASDAQ:NVAX) far more heavily than the rest of biotech. Novavax stock is surging 22% during afternoon trading to reach $12.73, a move that stands well apart from Novavax’s closest vaccine rivals and the broader sector.

Checking in on the peers, Moderna (NASDAQ:MRNA) stock is rose 8% to $204.62, a sharp gain tied to the company’s own cancer pipeline. Meanwhile, BioNTech (NASDAQ:BNTX) shares are barely higher, up 0.5% to $97.39. Two of the three best-known names in COVID vaccines are telling different stories.

For sector-level context, the iShares Biotechnology ETF (NASDAQ:IBB) is also up 1%. As a broad-market gauge, the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is gaining 0.7%, leaving Novavax stock running far ahead of both its sector fund and the market overall. That gap points to a rally concentrated in one name.

Sanofi Carries Nuvaxovid Into the Season

Nuvaxovid is Novavax’s protein-based COVID vaccine, built on a different platform from the messenger RNA (mRNA) technology behind Moderna’s and BioNTech’s shots. Sanofi now holds the U.S. approval for Nuvaxovid under a license from Novavax, and the partner is rolling the vaccine out in the United Kingdom, Germany and Canada. This arrangement gives Novavax exposure to a wider season through a larger commercial partner.

In late August, the Food and Drug Administration approved updated COVID vaccines adapted to the dominant XFG subvariant. Novavax has described the XFG-adapted Nuvaxovid approvals as evidence that its partnership strategy is working.

Novavax Moves Apart From Its Sector

A gain this large in low-priced Novavax stock raises the possibility of a short squeeze, where traders who sold borrowed shares rush to buy them back and push the price higher. Data on Novavax’s short interest isn’t available, so a squeeze stays on the list of possible explanations without confirmation.

Moderna stock’s sharp rose complicates any clean sector reading, since that rally leans on the company’s oncology story, while BioNTech stock, barely higher, offers little evidence that vaccine developers as a group are catching a bid. That mix leaves Novavax stock standing largely on its own among vaccine names.

What the Royalty Model Means for Novavax

What separates Novavax from both rivals is the business model. Under Novavax’s licensing strategy, partners manufacture and sell the vaccine while Novavax takes in royalty and milestone payments on those sales. Moderna and BioNTech still carry their own commercial operations.

That structure caps what a strong vaccination season can do for Novavax, since Sanofi books the product revenue and Novavax receives a share, and the same arrangement limits what a weak season can cost Novavax, because the partner carries the expense of selling the shot. For Novavax, the trade-off narrows the range of outcomes in both directions.

What to Watch Next

Sanofi’s U.S. rollout and the overseas launches could shape how much royalty revenue flows back to Novavax over the season. The question now is whether NVAX stock holds the bulk of the gain once the momentum cools off.

Novavax’s royalty math stays the same whichever way the stock trades from here, since payments follow Sanofi’s sales. In any case, NVAX stock at 52-week highs could be overextended, so position sizes should remain small and carefully maintained.

Contact [email protected] for any questions or corrections.